POZEN Receives Initial FDA Response To PA32540 SPA - MarketWatch

POZEN Receives Initial FDA Response To PA32540 SPA MarketWatch - 10 hours ago ... our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our ... FDA Strikes Another Blow to Amgen's Anemic Drug Sales istockAnalyst.com all 326 news articles

Source: http://news.google.com/news/url?sa=T&ct=us/8-0&fd=R&url=http://www.marketwatch.com/news/story/pozen-receives-initial-fda-response/story.aspx%3Fguid%3D%257BCDD43114-2F6E-40A1-BA23-1742F2E1F5D8%257D%26dist%3Dhppr&cid=1231325798&ei=9f6TSI-tDYK6ywSe_sjaBA&usg=AFQjCNHLPTVycFgHdn7ojKTfw-6GA8BgwQ